Systemic lupus erythematosus and accelerated atherosclerosis.
Hahn
Bevra Hannahs
BH
David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, USA.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001161:Arteriosclerosis / Q000209:etiology*; D002340:Carotid Artery Diseases / Q000209:etiology; D003324:Coronary Artery Disease / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide